Promising New Treatment for Patients with HR+ HER- newswise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswise.com Daily Mail and Mail on Sunday newspapers.
ADCs are rapidly changing the treatment landscape for patients with metastatic breast cancer, with the agents demonstrating improved efficacy and manageable risks.
Trastuzumab deruxtecan demonstrated superior long-term survival and response rates vs treatment of physician’s choice in HER2-positive breast cancer.